Programs and Projects

Prostate Cancer Clinical Trials - University of California, Irvine

Agent: DFMO
Contact: Frank Meyskens, M.D.
DCP Program Director: Howard Parnes, M.D.

The purpose of this study is to see if an oral medication called eflornithine (DFMO) can reduce the prevalence of prostate cancer in men with a strong family history of prostate cancer. These participants should have no personal history of prostate cancer but either brothers or first cousins who have had the disease. This study is now closed to accrual.

[This is a phase 2 randomized double-blind placebo controlled chemoprevention trial of DFMO administered for one year in men with a strong family history (brothers and first cousins) of prostate cancer. The primary endpoint is modulation of prostatic polyamines at one year.]